Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > List goes on and on
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(649)
•••
Comment by DeathXray33on Nov 23, 2023 1:07pm
139 Views
Post# 35750282

RE:RE:RE:RE:RE:RE:RE:RE:List goes on and on

RE:RE:RE:RE:RE:RE:RE:RE:List goes on and on
99942Apophis wrote:
skys1 wrote: Agree enriquesuave & Longholder. Back in April I posted that there had to be a reason why the FDA moved the goal posts and asked possibly for 18 months of data rather than 12. The FDA has in the past approved both BTD & AA together when there was a serious need. IMO, the current NMIBC situatuation with the shortage of BCG and the serious side effects of the current Standared of Care to the point many oncologists refuse to put their patients throught that "torture", qualifies TLT's ACT for that move.
It has now been a little over the 6 months needed to acquire that extra data so if in fact that is the reason for that FDA move, we should be getting close to them being able to make their decision. It would also explain why TLT decided to contract with an experienced outside firm to gather, organize, and submit this extra data to the FDA. 
Can you imagine what would happen to the share price if TLT got both BTD & AA at the same time?

More speculation on my part,  I believe we all know the answer to this might be because Theralase's treatment is a contender for SOC for NMIBC hence the need of 18 months of data. 


My bid on the ask wouldn't fill Wednesday...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities